GLAUKOS CORP

Company Overview

Glaukos Corp. is a Healthcare sector company in the Medical Devices industry focused on ophthalmic pharmaceutical and device therapies, especially “dropless” treatments for glaucoma, corneal disorders, and other anterior/posterior segment eye diseases. Its business is anchored by the iStent family of MIGS devices, iDose TR, and corneal treatments like Photrexa and Epioxa, with growing efforts in retinal and ocular-surface programs. Recent filings show strong revenue growth driven by iDose TR adoption and international glaucoma sales, but also highlight meaningful reimbursement, product-transition, and regulatory complexity. The company operates in a highly specialized, clinically driven market with a large U.S. footprint and broad international distribution.

Executive Compensation Practices

For a Medical Devices company like Glaukos, executive compensation is likely tied heavily to commercial execution, product adoption, reimbursement milestones, and pipeline advancement rather than only profitability. The filings suggest key performance drivers include U.S. glaucoma sales growth, iDose TR reimbursement consistency, Epioxa commercialization, R&D progress, and regulatory approvals, all of which are the kinds of metrics that can influence bonus and equity outcomes. Because the company is still reporting net losses and investing heavily in commercial infrastructure and clinical development, compensation may emphasize long-term equity awards, stock options, and milestone-based incentives to align management with future product launches and margin expansion. The disclosures about rising stock-based compensation also suggest equity is an important part of the reward structure, which is common in innovation-heavy healthcare businesses.

Insider Trading Considerations

Insider trading activity in Glaukos should be viewed through the lens of recurring regulatory and reimbursement catalysts, which can create sharp stock reactions around FDA decisions, HCPCS/J-code changes, Medicare coverage shifts, and clinical readouts. Trading patterns may also reflect management’s views on the pace of iDose TR adoption, the Photrexa-to-Epioxa transition, and the timing of large capital projects such as the Huntsville facility, since these directly affect near-term cash needs and growth expectations. In Medical Devices, insiders often face trading constraints around product approvals, payer coverage updates, and earnings windows because those events can materially change sentiment and valuation. For researchers and traders, purchases around pipeline milestones could signal confidence in reimbursement and launch execution, while sales may reflect diversification or liquidity needs during periods of elevated equity compensation and volatility.